載入...
Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond
Significant advances in the treatment of metastatic colorectal cancer (mcrc) since the early 2000s have led to improved clinical outcomes, including overall survival (os). When fluorouracil was the sole treatment agent for mcrc, os in phase iii studies was approximately 12 months. Now, in 2019, the...
Na minha lista:
| 發表在: | Curr Oncol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Multimed Inc.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6878937/ https://ncbi.nlm.nih.gov/pubmed/31819708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.5589 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|